Medistim ASA has transferred 9.000 shares to Medistim CEO, Kari E. Krogstad, at the last traded share price in 2023, of 214 NOK per share. This is in accordance with her compensation agreement with the company, as described in the Company's Annual Report. After the transfer, Kari E. Krogstad holds a total of 47.083 shares.

According to the CEO's share program she is entitled to receiving another 7.500 shares if in position 1st of January 2025 and another 8.000 shares if in position 1st of January 2026. A new agreement is entered between the company and the CEO, related to this share program. The CEO 100% owned company, K2 Consulting AS, has purchased the shares from Medistim ASA with a lock in period of 1 year for the 7.500 shares and a lock in period of 2 years for the 8.000 shares. The lock in period of 1 year qualifies for a 14 % share price discount and the 2 year lock in period qualifies for an 18% discount. Average share price in the 14 days subscription period was NOK 216 per share. 7.500 shares was therefore purchased at NOK 185,83 per share and 8.000 shares was purchased at NOK 177,19 per share. To finance the purchase, Medistim has given the CEO a loan and when the lock in period has ended, she is given a bonus equal to the loan amount.  K2 Consulting AS has in total purchased 15.500 shares at an average price of NOK 181,37 per share. After the purchase K2 Consulting AS holds 15.500 Medistim shares.

After these transactions Kari E. Krogstad controls in total 62.583 Medistim shares. Medistim ASA has 31.117 own shares after the transactions.